Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 6
2006 3
2010 3
2011 3
2012 5
2013 1
2014 5
2015 4
2016 4
2017 7
2018 8
2019 2
2020 1
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Deek MP, et al. Among authors: lambert b. J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24. J Clin Oncol. 2022. PMID: 36001857 Free PMC article.
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G. Ost P, et al. Among authors: lambert b. J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14. J Clin Oncol. 2018. PMID: 29240541 Clinical Trial.
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial.
Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, Aerts M, Vanlander A, Berrevoet F, Troisi RI, Van Vlierberghe H, Defreyne L. Dhondt E, et al. Among authors: lambert b. Radiology. 2022 Jun;303(3):699-710. doi: 10.1148/radiol.211806. Epub 2022 Mar 8. Radiology. 2022. PMID: 35258371 Clinical Trial.
Renal toxicity after radionuclide therapy.
Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA, Otte A. Lambert B, et al. Radiat Res. 2004 May;161(5):607-11. doi: 10.1667/rr3105. Radiat Res. 2004. PMID: 15161361 Review.
18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, Piron S, Lumen N, Decaestecker K, Fonteyne V, Delrue L, De Vos F, Ost P. De Man K, et al. Among authors: lambert b. Eur Urol. 2022 Nov;82(5):501-509. doi: 10.1016/j.eururo.2022.05.010. Epub 2022 Jun 8. Eur Urol. 2022. PMID: 35690515 Clinical Trial.
Guidelines on nuclear medicine imaging in neuroblastoma.
Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, Manea I, Koziorowski J, Castellani R, Boubaker A, Lambert B, Pfluger T, Nadel H, Sharp S, Giammarile F. Bar-Sever Z, et al. Among authors: lambert b. Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):2009-2024. doi: 10.1007/s00259-018-4070-8. Eur J Nucl Med Mol Imaging. 2018. PMID: 29938300
51 results